FDA Approval Alert: The Need-to-Know | Alectinib for Early-Stage ALK+ NSCLC

In April 2024, the FDA approved alectinib for the adjuvant treatment of patients with ALK-positive non–small cell lung cancer with tumors that are at least 4 cm or node-positive as detected by an FDA-approved test.

D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Alectinib “First of Many Approvals” In ALK+ NSCLC
Video
May 1, 2024 6:00 PM
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
FDA Approves Alectinib for Early-Stage ALK+ NSCLC
FDA Approves Alectinib for Early-Stage ALK+ NSCLC
Article
Apr 18, 2024 9:29 PM
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.